Liquidia Technologies to collaborate with Abbott on siRNA therapeutics



A dual-headed dedicated gamma camera used during molecular breast imaging (MBI) can accurately detect small breast tumors less than 2 cm in size, according to a study performed at the Mayo Clinic in Rochester, MN. One-hundred fifty patients who had suspicious lesions smaller than 2 cm in size were imaged using dual-head molecular breast imaging.

Full Post: Dual-headed dedicated gamma camera accurately detects small breast tumors

Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia’s PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

“Delivery has been the most significant hurdle to realizing the broad potential of siRNA therapeutics. We are very pleased to form a partnership with Abbott, which we hope will enable significant progress in addressing this problem,” said Neal Fowler, Chief Executive Officer of Liquidia. “By combining Abbott’s research and development capabilities with Liquidia’s particle design and delivery expertise, we hope to enable the use of siRNA for therapy and provide more targeted, effective treatment options for cancer patients.”

Under the terms of the agreement, Liquidia will provide Abbott with certain rights to PRINT technology for the development and commercialization of siRNA therapeutics. Financial terms were not disclosed.

About siRNA Therapeutics - Short interfering RNA (siRNA) are small, double stranded RNA molecules that selectively silence and regulate the activity of human genes through the process of RNA interference (RNAi). Since many diseases are caused by the inappropriate expression of certain genes, the ability to selectively silence disease-associated genes represents a novel and powerful method for treating disease. The primary challenge to achieving broad application of siRNA therapeutics is effective delivery of the molecules to target tissues and cell types.

http://www.liquidia.com

Link




Levels of two proteins in a woman’s ovarian cancer are strongly associated with her likelihood of survival, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Dec. 18 issue of the New England Journal of Medicine. The study shows that women with high levels of

Full Post: Levels of two proteins impact survival in ovarian cancer



Ovarian cancer cells are “addicted” to a family of proteins produced by the notorious oncogene, MYC. Blocking these Myc proteins halts cell proliferation in the deadliest cancer of the female reproductive system, according to a presentation by University of California, Berkeley scientists at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17,

Full Post: Blocking Myc proteins stops ovarian cancer cell cycle in its tracks



Ovarian cancer cells are “addicted” to a family of proteins produced by the notorious oncogene, MYC, and blocking these Myc proteins halts cell proliferation in the deadliest cancer of the female reproductive system, according to a presentation by University of California, Berkeley scientists at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec.

Full Post: Researchers stop ovarian cancer cell cycle in its tracks



Abbott and Advanced Medical Optics (AMO) have announced a definitive agreement for Abbott to acquire AMO for $22 per share in cash, for a total transaction value of approximately $2.8 billion, inclusive of estimated net debt at the time of closing. Based in Santa Ana, Calif., AMO is a global leader in ophthalmic care, comprised

Full Post: Abbott to acquire Advanced Medical Optics



Wyeth Pharmaceuticals, a division of Wyeth, and Santaris Pharma have announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means to

Full Post: Wyeth and Santaris Pharma to collaborate on RNA-based medicines